A rheumatoid arthritis medication also has benefit for those with ulcerative colitis.
Pfizer’s rheumatoid arthritis drug Xeljanz (tofacitinib) has met primary and key secondary endpoints in two phase trials to treat ulcerative colitis (UC).
In the Octave Induction 1 and Octave Induction 2 studies, tofacitinib reduced symptoms of moderate to severe UC and induced remission of the disease.
In one study, 18.5% of patients who received 10 milligrams of tofacitinib twice a day achieved remission, including no rectal bleeding, after eight weeks compared to 8.2% of patients who received a placebo.
In another study, 16.6% of tofacitinib patients achieved remission, versus 3.6% for placebo.
A significantly higher number of tofacitinib patients also experienced mucosal healing, which the key secondary endpoint in both trials.
Pfizer said safety findings for tofacitinib in both the studies were similar to those found in other tofacitinib investigational clinical trials.
UC is expected to lead to complex interactions between various factors such as the environment, genetic predisposition, immune response, and the gut microbiome in the colon or intestines.
|Read Full Article: Pfizer’s Xeljanz rheumatoid arthritis drug meets endpoints in ulcerative colitis trials – Pharmaceutical Business Review|